Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797393 | 1.00 | MALT1 (0.41) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL13123207 | 0.85 | MALT1 (0.47) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL6033555 | 0.82 | MALT1 (0.53) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL13123195 | 0.79 | MALT1 (0.47) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL13123193 | 0.77 | MALT1 (0.38) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL12473069 | 0.72 | MALT1 (0.65) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL18774056 | 0.72 | MALT1 (0.65) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL883642 | 0.71 | MALT1 (0.53) | MALT1KMT2AIDO1KDM4EMEN1 | |
| SCHEMBL3799030 | 0.71 | KMT2A (0.55) | KMT2AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL18774148 | 0.71 | MALT1 (0.55) | MALT1KMT2AIDO1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812051-B2 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2006020722-A2 | POLYMER CONJUGATES OF BETA-LAPACHONE AND BETA-LAPACHONE ANALOGS FOR TUMOR TARGETING | ARQULE, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | ARQULE, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | NQO1, KEAP1, DLD | MALT1 2824/4885KMT2A 3402/4885IDO1 3400/4885 |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | QPCT, KEAP1, SLC46A1 | MALT1 2320/4885KMT2A 1490/4885IDO1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.